Bone Abstracts

Background: In postmenopausal osteoporosis, a loss of bone volume due to increased bone turnover is accompanied by a higher volume of bone marrow adipose tissue (BMAT). If this static relationship is based on a functional relationship, BMAT is a potential target for treating osteoporosis. While it is known that estrogen can reduce BMAT, it is still unknown whether raloxifene – a selective estrogen receptor modulator – can also reduce BMAT.Objec...

Background: In postmenopausal osteoporosis, a loss of bone volume due to increased bone turnover is accompanied by a higher volume of bone marrow adipose tissue (BMAT). If this static relationship is based on a functional relationship, BMAT is a potential target for treating osteoporosis. While it is known that estrogen can reduce BMAT, it is still unknown whether raloxifene – a selective estrogen receptor modulator – can also reduce BMAT.Objec...

Objective: The aim of this study was to gain insight into all the current overall costs (direct medical, direct non-medical and indirect costs) of clinical fractures in osteoporotic patients aged 50 years and older in the Netherlands.Materials and methods: This prospective study was part of a larger study in which the effect of a fracture nurse on diagnosis and subsequent treatment of elderly osteoporotic patients with a recent fracture was assessed. Inc...

Objective: Increase the percentage of elderly fracture patients undergoing a dual energy X-ray absorptiometry (DXA) measurement, and investigate why some patients did not respond to invitation to our fracture liaison service (FLS).Materials and methods: In four Dutch hospitals, fracture patients ≥50 years were invited for a DXA measurement and visit to our FLS. Patients who did not respond, were contacted by telephone. In patients diagnosed with os...

Preterm infants develop reduced bone mass and fragility fractures. Nevertheless, normal ranges in preterm infants are poorly defined for concentrations of vitamin D; its isomers (C3α-epimer of 25(OH)D3) and metabolites (24, 25(OH)2D3, 1, 24(OH)2D); and other mineral-regulating hormones, including FGF23 in both intact (iFRG23) and inactive (C- terminal) forms.Objective: To clarify normal concentrations of minerals and hormones in healthy, preterm inf...